STAAR Surgical Management

Management Kriterienprüfungen 1/4

STAAR Surgical CEO ist Tom Frinzi , ernannt in Jan 2023, hat eine Amtszeit von 1.83 Jahren. Die jährliche Gesamtvergütung beträgt $10.22M , bestehend aus 7.7% Gehalt und 92.3% Boni, einschließlich Aktien und Optionen des Unternehmens. besitzt direkt 0.046% der Aktien des Unternehmens, im Wert von $606.05K . Die durchschnittliche Betriebszugehörigkeit des Managementteams und des Verwaltungsrats beträgt 1.8 Jahre bzw. 3.1 Jahre.

Wichtige Informationen

Tom Frinzi

Geschäftsführender

US$10.2m

Gesamtvergütung

Prozentsatz des Geschäftsführergehalts7.7%
Amtszeit als Geschäftsführer1.8yrs
Eigentum des Geschäftsführers0.05%
Durchschnittliche Amtszeit des Managements1.8yrs
Durchschnittliche Amtszeit der Vorstandsmitglieder3.1yrs

Jüngste Management Updates

Recent updates

Return Trends At STAAR Surgical (NASDAQ:STAA) Aren't Appealing

Oct 24
Return Trends At STAAR Surgical (NASDAQ:STAA) Aren't Appealing

STAAR Surgical: Expecting A Re-Acceleration In Growth As Investments Materialize

Sep 05

Results: STAAR Surgical Company Exceeded Expectations And The Consensus Has Updated Its Estimates

Aug 10
Results: STAAR Surgical Company Exceeded Expectations And The Consensus Has Updated Its Estimates

STAAR Surgical Company's (NASDAQ:STAA) Popularity With Investors Is Clear

Aug 05
STAAR Surgical Company's (NASDAQ:STAA) Popularity With Investors Is Clear

The Returns At STAAR Surgical (NASDAQ:STAA) Aren't Growing

Jul 12
The Returns At STAAR Surgical (NASDAQ:STAA) Aren't Growing

Is There Now An Opportunity In STAAR Surgical Company (NASDAQ:STAA)?

May 27
Is There Now An Opportunity In STAAR Surgical Company (NASDAQ:STAA)?

Market Participants Recognise STAAR Surgical Company's (NASDAQ:STAA) Revenues Pushing Shares 30% Higher

Apr 26
Market Participants Recognise STAAR Surgical Company's (NASDAQ:STAA) Revenues Pushing Shares 30% Higher

STAAR Surgical Stock: I Don't See A Great Path Forward, Despite The Recent Surge

Apr 05

STAAR Surgical (NASDAQ:STAA) Shareholders Will Want The ROCE Trajectory To Continue

Mar 25
STAAR Surgical (NASDAQ:STAA) Shareholders Will Want The ROCE Trajectory To Continue

STAAR Surgical Company: Potential Buy After Long-Term Valuation Downgrade

Mar 13

STAAR Surgical Company (NASDAQ:STAA) Looks Just Right With A 28% Price Jump

Mar 07
STAAR Surgical Company (NASDAQ:STAA) Looks Just Right With A 28% Price Jump

Is There Now An Opportunity In STAAR Surgical Company (NASDAQ:STAA)?

Jan 31
Is There Now An Opportunity In STAAR Surgical Company (NASDAQ:STAA)?

With STAAR Surgical Company (NASDAQ:STAA) It Looks Like You'll Get What You Pay For

Jan 05
With STAAR Surgical Company (NASDAQ:STAA) It Looks Like You'll Get What You Pay For

Returns On Capital Are Showing Encouraging Signs At STAAR Surgical (NASDAQ:STAA)

Nov 30
Returns On Capital Are Showing Encouraging Signs At STAAR Surgical (NASDAQ:STAA)

Is There An Opportunity With STAAR Surgical Company's (NASDAQ:STAA) 21% Undervaluation?

Nov 12
Is There An Opportunity With STAAR Surgical Company's (NASDAQ:STAA) 21% Undervaluation?

Is STAAR Surgical Company (NASDAQ:STAA) Potentially Undervalued?

Oct 25
Is STAAR Surgical Company (NASDAQ:STAA) Potentially Undervalued?

Returns On Capital At STAAR Surgical (NASDAQ:STAA) Have Hit The Brakes

Aug 24
Returns On Capital At STAAR Surgical (NASDAQ:STAA) Have Hit The Brakes

Are STAAR Surgical Company (NASDAQ:STAA) Investors Paying Above The Intrinsic Value?

Jul 02
Are STAAR Surgical Company (NASDAQ:STAA) Investors Paying Above The Intrinsic Value?

Is Now The Time To Look At Buying STAAR Surgical Company (NASDAQ:STAA)?

Jun 17
Is Now The Time To Look At Buying STAAR Surgical Company (NASDAQ:STAA)?

Here's Why We Think STAAR Surgical (NASDAQ:STAA) Might Deserve Your Attention Today

May 13
Here's Why We Think STAAR Surgical (NASDAQ:STAA) Might Deserve Your Attention Today

A Look At The Fair Value Of STAAR Surgical Company (NASDAQ:STAA)

Mar 26
A Look At The Fair Value Of STAAR Surgical Company (NASDAQ:STAA)

STAAR Surgical (NASDAQ:STAA) Is Looking To Continue Growing Its Returns On Capital

Mar 12
STAAR Surgical (NASDAQ:STAA) Is Looking To Continue Growing Its Returns On Capital

Should You Investigate STAAR Surgical Company (NASDAQ:STAA) At US$68.56?

Feb 13
Should You Investigate STAAR Surgical Company (NASDAQ:STAA) At US$68.56?

Here's Why We Think STAAR Surgical (NASDAQ:STAA) Might Deserve Your Attention Today

Jan 28
Here's Why We Think STAAR Surgical (NASDAQ:STAA) Might Deserve Your Attention Today

Calculating The Fair Value Of STAAR Surgical Company (NASDAQ:STAA)

Dec 15
Calculating The Fair Value Of STAAR Surgical Company (NASDAQ:STAA)

The Return Trends At STAAR Surgical (NASDAQ:STAA) Look Promising

Dec 01
The Return Trends At STAAR Surgical (NASDAQ:STAA) Look Promising

What Is STAAR Surgical Company's (NASDAQ:STAA) Share Price Doing?

Oct 26
What Is STAAR Surgical Company's (NASDAQ:STAA) Share Price Doing?

Keep Adding To STAAR Surgical Longs, Buy Thesis Remains

Sep 20

Should You Be Adding STAAR Surgical (NASDAQ:STAA) To Your Watchlist Today?

Sep 05
Should You Be Adding STAAR Surgical (NASDAQ:STAA) To Your Watchlist Today?

STAAR Surgical Company (NASDAQ:STAA) Shares Could Be 24% Above Their Intrinsic Value Estimate

Aug 21
STAAR Surgical Company (NASDAQ:STAA) Shares Could Be 24% Above Their Intrinsic Value Estimate

STAAR Surgical rises 15% on Q2 result beat

Aug 11

Analyse der Geschäftsführervergütung

Wie hat sich die Vergütung von Tom Frinzi im Vergleich zu den Einnahmen von STAAR Surgical verändert?
DatumGesamtvergütungGehaltUnternehmensgewinne
Sep 27 2024n/an/a

US$22m

Jun 28 2024n/an/a

US$17m

Mar 29 2024n/an/a

US$15m

Dec 29 2023US$10mUS$788k

US$21m

Sep 29 2023n/an/a

US$20m

Jun 30 2023n/an/a

US$26m

Mar 31 2023n/an/a

US$33m

Dec 30 2022US$274kn/a

US$40m

Sep 30 2022n/an/a

US$38m

Jul 01 2022n/an/a

US$34m

Apr 01 2022n/an/a

US$29m

Dec 31 2021US$250kn/a

US$28m

Oct 01 2021n/an/a

US$23m

Jul 02 2021n/an/a

US$21m

Apr 02 2021n/an/a

US$11m

Jan 01 2021US$182kn/a

US$6m

Vergütung im Vergleich zum Markt: TomDie Gesamtvergütung ($USD10.22M) liegt über dem Durchschnitt von Unternehmen ähnlicher Größe auf dem Markt US ($USD5.37M).

Entschädigung vs. Einkommen: TomDie Bezüge der Mitarbeiter sind im vergangenen Jahr um mehr als 20 % gestiegen.


Geschäftsführer

Tom Frinzi (68 yo)

1.8yrs

Amtszeit

US$10,220,581

Vergütung

Mr. Thomas G. Frinzi, also known as Tom, serves as Executive Chairman of the Board at ViaLase, Inc. since November 2022 and joined the company in November 2022. He serves as Executive Chair at Aurion Biote...


Führungsteam

NamePositionAmtszeitVergütungEigentümerschaft
Thomas Frinzi
President1.8yrsUS$10.22m0.046%
$ 606.0k
Patrick Williams
Chief Financial Officer4.3yrsUS$2.82m0.070%
$ 912.7k
Warren Foust
Chief Operating Officer1.6yrsUS$3.42m0.0089%
$ 116.1k
Keith Holliday
Chief Technology Officer7.7yrsUS$2.41m0.036%
$ 473.3k
Scott Barnes
Chief Medical Officer7.1yrsUS$2.48m0.064%
$ 834.6k
Brian Moore
Vice President of Investor Relations & Corporate Developmentno datakeine Datenkeine Daten
Nathaniel Sisitsky
General Counsel & Corporate Secretaryless than a yearkeine Datenkeine Daten
Nancy Sabin
Chief Marketing Officerless than a yearkeine Datenkeine Daten
James Francese
Senior Vice President of Commercial Operations - North America & APAC8yrsUS$2.54m0.060%
$ 789.7k
Magda Michna
Chief Clinical1.6yrskeine Daten0.0061%
$ 80.2k
Robert Studholme
Senior Vice President of Operationsno datakeine Daten0.066%
$ 865.0k

1.8yrs

Durchschnittliche Betriebszugehörigkeit

60.5yo

Durchschnittliches Alter

Erfahrenes Management: STAADas Führungsteam des Unternehmens gilt nicht als erfahren ( 1.8 Jahre durchschnittliche Betriebszugehörigkeit), was auf ein neues Team schließen lässt.


Vorstandsmitglieder

NamePositionAmtszeitVergütungEigentümerschaft
Thomas Frinzi
President4.4yrsUS$10.22m0.046%
$ 606.0k
Stephen Farrell
Lead Independent Director8.8yrsUS$294.87k0.031%
$ 403.6k
Aimee Weisner
Independent Director2.4yrsUS$259.96k0.031%
$ 408.9k
Lilian Zhou
Independent Directorless than a yearUS$99.69k0.0093%
$ 121.7k
Brian Williams
Member of Optometric Advisory Council16yrskeine Datenkeine Daten
Arthur Crosswell Butcher
Independent Directorless than a yearkeine Daten0.0085%
$ 112.0k
Wei Jiang
Independent Directorless than a yearkeine Daten0.0072%
$ 94.3k
Elizabeth Yeu
Independent Director3.8yrsUS$249.99k0.010%
$ 135.8k

3.1yrs

Durchschnittliche Betriebszugehörigkeit

55yo

Durchschnittliches Alter

Erfahrener Vorstand: STAADie Vorstandsmitglieder gelten als erfahren (3.1 Jahre durchschnittliche Amtszeit).